Brokerages Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Target Price at $127.44

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given an average rating of “Moderate Buy” by the nineteen analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $126.00.

BNTX has been the subject of a number of analyst reports. Citigroup reduced their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. UBS Group raised BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $117.00 to $135.00 in a research note on Wednesday, May 27th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research note on Monday, June 1st.

More BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech and partner OncoC4 reported that gotistobart nearly doubled median overall survival compared with standard chemotherapy in previously treated patients with squamous non-small-cell lung cancer. The Phase 3 PRESERVE-003 trial evaluated patients whose disease had progressed after immunotherapy and chemotherapy, supporting the drug’s potential as a differentiated oncology treatment. BioNTech and OncoC4 present updated gotistobart data
• Positive Sentiment: The survival results prompted reports that BNTX shares rose as much as approximately 6.4%. Investors appear to be viewing the data as a potentially important validation of BioNTech’s strategy to expand beyond COVID-19 vaccines and build an oncology pipeline. BioNTech says lung cancer candidate prolonged lives in trial
• Neutral Sentiment: Gotistobart, also known as BNT316 or ONC-392, is an investigational CTLA-4-targeting immunotherapy designed to reduce regulatory T cells in tumors and restore anti-tumor immune activity. The data are encouraging, but the treatment still faces further regulatory and clinical review before it can generate commercial revenue. BioNTech gotistobart overall survival data
• Negative Sentiment: CEO Ugur Sahin sold a combined 86,000 BioNTech shares for approximately $8.44 million across September 11 and September 14, reducing his holdings by roughly 13% in total. Both transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which limits the bearish signal, but the sales may still weigh modestly on investor sentiment. SEC insider transaction filing

BioNTech Stock Performance

BNTX opened at $98.86 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The firm has a fifty day moving average price of $97.08 and a 200 day moving average price of $95.19. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00. The stock has a market cap of $25.00 billion, a P/E ratio of -12.63 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the previous year, the firm posted ($1.60) EPS. The firm’s quarterly revenue was down 59.5% on a year-over-year basis. Equities research analysts anticipate that BioNTech will post -6.33 earnings per share for the current year.

Insider Transactions at BioNTech

In other news, CEO Ugur Sahin sold 45,000 shares of BioNTech stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $102.85, for a total value of $4,628,250.00. Following the sale, the chief executive officer owned 813,209 shares in the company, valued at $83,638,545.65. This trade represents a 5.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 256,000 shares of company stock worth $25,493,265 over the last quarter. Company insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BNTX. Larson Financial Group LLC lifted its stake in BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in BioNTech during the second quarter worth $39,000. Caitong International Asset Management Co. Ltd grew its holdings in BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after buying an additional 506 shares in the last quarter. Vestcor Inc acquired a new stake in shares of BioNTech in the 4th quarter worth $153,000. Finally, Rockefeller Capital Management L.P. increased its stake in shares of BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after acquiring an additional 1,423 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.